Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes

Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients with type 2 diabetes mellitus with or without other antidiabetic drugs for 6 months to evaluate its efficacy, the incidence of adverse events,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosaki, Takahiro, Kamiya, Hideki, Himeno, Tatsuhito, Kato, Yoshiro, Kondo, Masaki, Toyota, Kaori, Nishida, Tomoyo, Shiroma, Megumi, Tsubonaka, Kaori, Asai, Hitomi, Moribe, Miho, Nakaya, Yuki, Nakamura, Jiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410466/
https://www.ncbi.nlm.nih.gov/pubmed/28321056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410466/
https://www.ncbi.nlm.nih.gov/pubmed/28321056

Ejemplares similares